TNT003 / Sanofi - LARVOL DELTA

Development of a flow cytometric assay to identify complement-activating antibodies in ITP patients (ISTH 2025) - "Results Binding of mIgM or mIgG2a anti-GPIIb-IIIa to HD platelets resulted in increased platelet surface C4d and C3b, which was completely blocked by antibodies directed against C1s, TNT-003 or TNT-005...However, in a subset of ITP patients, C3b-positivity and C4d-positivity were higher than the highest values in HDs (Fig.2). Table or Figure Upload"

Clinical • Hematological Disorders • Immune Thrombocytopenic Purpura • Thrombocytopenia • Thrombocytopenic Purpura

C1s targeting antibodies inhibit the growth of cutaneous squamous carcinoma cells. (PubMed, Sci Rep) - "Treatment of cSCC cells with TNT003 and TNT005 significantly inhibited their growth and viability and promoted apoptosis of cSCC cells. These data indicate that TNT003 and TNT005 inhibit cSCC cell growth in culture and warrant further investigation of C1s targeted inhibition in additional in vitro and in vivo models of cSCC."

Journal • Actinic Keratosis • Dermatology • Genetic Disorders • Oncology • Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Inhibition of the Classical Pathway of Complement with Sutimlimab in Chronic Immune Thrombocytopenic Purpura Patients without Adequate Response to Two or More Prior Therapies (ASH 2019) - "Inhibition of the CP in vitro with TNT003, a monoclonal C1s antibody, decreases deposition of C3b and C5b-9 on plts when exposed to ITP patient sera. This is the first clinical evidence that the CP plays a role in thrombocytopenia in a subset of patients with ITP. These responses suggest at least 1 additional pathophysiologic explanation for the clinical heterogeneity of ITP, and provide a strong rationale for continued evaluation of CP inhibition in ITP treatment."

Clinical